SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In
 
We’re going down soon, to move to a new Data Center today.  We’ll be up ASAP.  Sorry.

Biolase, Inc – ‘10-Q’ for 3/31/20 – ‘R30’

On:  Friday, 5/8/20, at 3:11pm ET   ·   For:  3/31/20   ·   Accession #:  1564590-20-23480   ·   File #:  1-36385

Previous ‘10-Q’:  ‘10-Q’ on 11/12/19 for 9/30/19   ·   Next:  ‘10-Q’ on 8/14/20 for 6/30/20   ·   Latest:  ‘10-Q’ on 11/9/23 for 9/30/23   ·   28 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/08/20  Biolase, Inc                      10-Q        3/31/20   86:8.5M                                   ActiveDisclosure/FA

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    638K 
 4: EX-10.10    Material Contract                                   HTML     30K 
 2: EX-10.8     Material Contract                                   HTML     63K 
 3: EX-10.9     Material Contract                                   HTML     30K 
 5: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 6: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
 8: EX-32.2     Certification -- §906 - SOA'02                      HTML     26K 
21: R1          Document and Entity Information                     HTML     78K 
69: R2          Consolidated Balance Sheets (Unaudited)             HTML    114K 
78: R3          Consolidated Balance Sheets (Unaudited)             HTML     51K 
                (Parenthetical)                                                  
50: R4          Consolidated Statements Of Operations And           HTML     95K 
                Comprehensive Loss (Unaudited)                                   
20: R5          Consolidated Statements Of Redeemable Preferred     HTML     53K 
                Stock and Stockholders' (Deficit) Equity                         
                (Unaudited)                                                      
68: R6          Consolidated Statements Of Cash Flows (Unaudited)   HTML    110K 
77: R7          Description of Business and Basis of Presentation   HTML     47K 
49: R8          Summary of Significant Accounting Policies          HTML     39K 
22: R9          Revenue Recognition                                 HTML    165K 
63: R10         Redeemable Preferred Stock and Stockholders'        HTML    243K 
                (Deficit) Equity                                                 
71: R11         Inventory                                           HTML     46K 
48: R12         Property, Plant, and Equipment                      HTML     67K 
19: R13         Intangible Assets and Goodwill                      HTML     29K 
62: R14         Accrued Liabilities                                 HTML     87K 
70: R15         Debt                                                HTML     98K 
47: R16         Leases                                              HTML     79K 
18: R17         Commitments and Contingencies                       HTML     35K 
61: R18         Segment Information                                 HTML     61K 
72: R19         Concentrations                                      HTML     74K 
42: R20         Income Taxes                                        HTML     31K 
34: R21         Subsequent Event                                    HTML     31K 
60: R22         Summary of Significant Accounting Policies          HTML    219K 
                (Policies)                                                       
86: R23         Revenue Recognition (Tables)                        HTML    206K 
41: R24         Redeemable Preferred Stock and Stockholders'        HTML    247K 
                (Deficit) Equity (Tables)                                        
33: R25         Inventory (Tables)                                  HTML     47K 
59: R26         Property, Plant, and Equipment (Tables)             HTML     66K 
85: R27         Accrued Liabilities (Tables)                        HTML     88K 
43: R28         Debt (Tables)                                       HTML     75K 
32: R29         Leases (Tables)                                     HTML     80K 
15: R30         Segment Information (Tables)                        HTML     62K 
45: R31         Concentrations (Tables)                             HTML    118K 
73: R32         Description of Business and Basis of Presentation   HTML     56K 
                - Additional Information (Detail)                                
64: R33         Revenue Recognition - Additional Information        HTML     34K 
                (Detail)                                                         
16: R34         Summary of Opening and Closing Balances of          HTML     37K 
                Contract Liabilities (Detail)                                    
46: R35         Summary of Disaggregation of Revenues Related to    HTML     32K 
                Geographic Areas (Detail)                                        
74: R36         Summary of Revenues Disaggregated by Timing of      HTML     32K 
                Goods and Services Transferred (Detail)                          
65: R37         Summary of Sales by End Market (Detail)             HTML     32K 
17: R38         Schedule of Revenue and Percentages of Revenue      HTML     49K 
                Sales by Product Line (Detail)                                   
44: R39         Redeemable Preferred Stock and Stockholders'        HTML     79K 
                (Deficit) Equity - Additional Information (Detail)               
29: R40         Classification of Compensation Expense Associated   HTML     37K 
                with Share-Based Payments (Detail)                               
39: R41         Assumptions Used in Estimating Fair Value of Stock  HTML     33K 
                Options Granted (Detail)                                         
80: R42         Summary of Option Activity (Detail)                 HTML     59K 
54: R43         Summary of Unvested Stock Option Activity (Detail)  HTML     46K 
30: R44         Cash Proceeds Along with Fair Value Disclosures     HTML     33K 
                Related to Grants, Exercises and Vested Options                  
                (Detail)                                                         
40: R45         Summary of Unvested Restricted Stock Units          HTML     50K 
                (Detail)                                                         
81: R46         Summary of Warrant Activity (Detail)                HTML     37K 
55: R47         Components of Inventory (Detail)                    HTML     35K 
31: R48         Inventory - Additional Information (Detail)         HTML     28K 
37: R49         Summary of Property, Plant, and Equipment (Detail)  HTML     49K 
52: R50         Property, Plant, and Equipment - Additional         HTML     27K 
                Information (Detail)                                             
26: R51         Intangible Assets and Goodwill - Additional         HTML     33K 
                Information (Detail)                                             
67: R52         Components of Accrued Liabilities (Detail)          HTML     48K 
76: R53         Changes in Initial Product Warranty Accrual and     HTML     41K 
                Expenses Under Initial and Extended Warranties                   
                (Detail)                                                         
51: R54         Accrued Liabilities - Additional Information        HTML     33K 
                (Detail)                                                         
25: R55         Debt - Summary of Principal Outstanding and         HTML     33K 
                Unamortized Discount (Detail)                                    
66: R56         Debt - Additional Information (Detail)              HTML    224K 
75: R57         Debt - Summary of Future Minimum Principal and      HTML     47K 
                Interest Payments (Detail)                                       
53: R58         Leases - Additional Information (Detail)            HTML     64K 
23: R59         Leases - Information related to Right-of-use        HTML     29K 
                Assets and Liabilities (Detail)                                  
58: R60         Leases - Schedule of Maturities of Lease            HTML     37K 
                Liabilities (Detail)                                             
83: R61         Leases - Future Minimum Rental Commitments Under    HTML     44K 
                Lease Agreements (Detail)                                        
36: R62         Commitments and Contingencies - Additional          HTML     57K 
                Information (Detail)                                             
28: R63         Segment Information - Additional Information        HTML     38K 
                (Detail)                                                         
57: R64         Summary of Net Revenue by Geographic Location       HTML     32K 
                (Detail)                                                         
82: R65         Summary of Property, Plant and Equipment by         HTML     33K 
                Geographic Location (Detail)                                     
35: R66         Concentrations - Summary of Net Revenue from        HTML     49K 
                Various Products (Detail)                                        
27: R67         Concentrations - Additional Information (Detail)    HTML     40K 
56: R68         Income Taxes - Additional Information (Detail)      HTML     36K 
84: R69         Subsequent Event - Additional Information (Detail)  HTML     51K 
24: XML         IDEA XML File -- Filing Summary                      XML    152K 
38: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
 9: EX-101.INS  XBRL Instance -- biol-20200331                       XML   2.24M 
11: EX-101.CAL  XBRL Calculations -- biol-20200331_cal               XML    170K 
12: EX-101.DEF  XBRL Definitions -- biol-20200331_def                XML    543K 
13: EX-101.LAB  XBRL Labels -- biol-20200331_lab                     XML   1.33M 
14: EX-101.PRE  XBRL Presentations -- biol-20200331_pre              XML   1.01M 
10: EX-101.SCH  XBRL Schema -- biol-20200331                         XSD    205K 
79: ZIP         XBRL Zipped Folder -- 0001564590-20-023480-xbrl      Zip    165K 


‘R30’   —   Segment Information (Tables)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.20.1
Segment Information (Tables)
3 Months Ended
Segment Reporting [Abstract]  
Summary of Net Revenue by Geographic Location

Net revenue by geographic location based on the location of customers was as follows (in thousands):  

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

United States

 

$

3,129

 

 

$

6,116

 

International

 

 

1,654

 

 

 

4,210

 

 

 

$

4,783

 

 

$

10,326

 

Summary of Property, Plant and Equipment by Geographic Location

Property, plant, and equipment by geographic location was as follows (in thousands):

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

United States

 

$

742

 

 

$

908

 

International

 

 

275

 

 

 

285

 

 

 

$

1,017

 

 

$

1,193

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
12/31/20
Filed on:5/8/20
For Period end:3/31/208-K
 List all Filings 


28 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/19/24  Biolase, Inc.                     POS AM                 1:1.1M                                   Donnelley … Solutions/FA
 4/11/24  Biolase, Inc.                     POS AM                 3:1.1M                                   Donnelley … Solutions/FA
 3/27/24  Biolase, Inc.                     S-1/A                  5:1.1M                                   Donnelley … Solutions/FA
 3/21/24  Biolase, Inc.                     10-K       12/31/23   99:18M                                    Donnelley … Solutions/FA
 2/09/24  Biolase, Inc.                     S-1/A                  4:3M                                     Donnelley … Solutions/FA
 2/07/24  Biolase, Inc.                     S-1/A                  8:3.3M                                   Donnelley … Solutions/FA
 1/31/24  Biolase, Inc.                     S-1/A                  9:3.2M                                   Donnelley … Solutions/FA
 1/19/24  Biolase, Inc.                     S-1                    3:2.6M                                   Donnelley … Solutions/FA
12/26/23  Biolase, Inc.                     S-1                    4:496K                                   Donnelley … Solutions/FA
 9/11/23  Biolase, Inc.                     S-1/A                  4:868K                                   Donnelley … Solutions/FA
 9/05/23  Biolase, Inc.                     S-1/A       9/01/23    2:830K                                   Donnelley … Solutions/FA
 8/30/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 8/18/23  Biolase, Inc.                     S-1/A                  2:720K                                   Donnelley … Solutions/FA
 8/14/23  Biolase, Inc.                     S-1/A       8/11/23    8:1.3M                                   Donnelley … Solutions/FA
 7/21/23  Biolase, Inc.                     S-1                    3:800K                                   Donnelley … Solutions/FA
 5/24/23  Biolase, Inc.                     S-1/A                  7:1.2M                                   Donnelley … Solutions/FA
 5/22/23  Biolase, Inc.                     S-1/A                  8:1.3M                                   Donnelley … Solutions/FA
 5/18/23  Biolase, Inc.                     S-1/A                  8:1.2M                                   Donnelley … Solutions/FA
 5/04/23  Biolase, Inc.                     S-1                    3:750K                                   Donnelley … Solutions/FA
 3/28/23  Biolase, Inc.                     10-K       12/31/22   90:19M                                    Donnelley … Solutions/FA
 1/03/23  Biolase, Inc.                     S-1/A                  6:1M                                     Donnelley … Solutions/FA
12/12/22  Biolase, Inc.                     S-1/A                  7:1.1M                                   Donnelley … Solutions/FA
11/22/22  Biolase, Inc.                     S-1                    3:655K                                   Donnelley … Solutions/FA
 3/17/22  Biolase, Inc.                     10-K       12/31/21   88:18M                                    Donnelley … Solutions/FA
 3/31/21  Biolase, Inc.                     10-K       12/31/20   88:15M                                    ActiveDisclosure/FA
 2/09/21  Biolase, Inc.                     424B5                  1:495K                                   Donnelley … Solutions/FA
12/15/20  Biolase, Inc.                     424B3                  1:392K                                   Donnelley … Solutions/FA
12/08/20  Biolase, Inc.                     S-1/A                  3:585K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001564590-20-023480   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., May 11, 8:54:50.3am ET